Amphastar Pharmaceuticals/$AMPH
1D1W1MYTD1Y5YMAX
Capital at risk
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
- Ticker
- $AMPH
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,976
- Headquarters
- Rancho Cucamonga, United States
- Website
- www.amphastar.com
AMPH Metrics
BasicAdvanced
$986M
13.74
$1.69
0.90
-
Price and volume
Market cap
$986M
Beta
0.9
52-week high
$29.78
52-week low
$16.65
Average daily volume
434K
Financial strength
Current ratio
2.397
Quick ratio
1.663
Long term debt to equity
88.137
Total debt to equity
89.607
Interest coverage (TTM)
6.32%
Profitability
EBITDA (TTM)
194.514
Gross margin (TTM)
47.68%
Net profit margin (TTM)
10.76%
Operating margin (TTM)
18.82%
Effective tax rate (TTM)
23.01%
Revenue per employee (TTM)
$370,000
Management effectiveness
Return on assets (TTM)
5.11%
Return on equity (TTM)
10.30%
Valuation
Price to earnings (TTM)
13.741
Price to revenue (TTM)
1.44
Price to book
1.28
Price to tangible book (TTM)
8.19
Price to free cash flow (TTM)
6.874
Free cash flow yield (TTM)
14.55%
Free cash flow per share (TTM)
3.372
Growth
Revenue change (TTM)
1.02%
Earnings per share change (TTM)
-37.04%
3-year revenue growth (CAGR)
10.51%
10-year revenue growth (CAGR)
10.53%
3-year earnings per share growth (CAGR)
-4.56%
10-year earnings per share growth (CAGR)
18.52%
What the Analysts think about AMPH
Analyst ratings (Buy, Hold, Sell) for Amphastar Pharmaceuticals stock.
Analyst projections of the future price of Amphastar Pharmaceuticals stock.
AMPH Financial Performance
Revenues and expenses
AMPH Earnings Performance
Company profitability
Upcoming events
No upcoming events
AMPH News
AllArticlesVideos
Funds containing AMPH
AllUSDGBPEUR
Fund name | Fund size | $AMPH weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.06% |
iShares Nasdaq US Biotechnology£BTEK | £867M | 0.06% |
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.04% |
iShares S&P Small Cap 600£ISP6 | £2.4B | 0.04% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.